{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:13:15Z","timestamp":1780704795376,"version":"3.54.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy with limited treatment options, particularly in elderly patients. HER2 overexpression has emerged as a potential therapeutic target in this disease. This study reports the case of an 86-year-old male with HER2-positive submandibular gland SDC who underwent surgical resection on June 19, 2020. Six months postoperatively, follow-up revealed lymph node metastasis and local recurrence at the left submandibular region. Ultrasound-guided radiofrequency ablation was performed, but local recurrence persisted. The patient subsequently received trastuzumab combined with low-dose nab-paclitaxel, achieving a partial response according to RECIST 1.1 criteria. Maintenance therapy with trastuzumab monotherapy was then initiated, resulting in disease stability for over 20 months. In October 2023, the disease progressed to the left sublingual region. After targeted monotherapy and local radiotherapy by April the following year, disease control was achieved. At the most recent follow-up, the patient remains in stable condition. This case highlights the efficacy and safety of HER2-targeted combination therapy in elderly SDC patients, offering valuable insights into biomarker-driven personalized treatment strategies for this population.<\/jats:p>","DOI":"10.3389\/fonc.2025.1590497","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:25Z","timestamp":1760933665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["HER2 inhibitor-based combination therapy for recurrent and metastatic salivary duct carcinoma in an elderly patient: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Luxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liujie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00301495","article-title":"Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma","volume":"192","author":"Kleinsasser","year":"1968","journal-title":"Arch Klin Exp Ohren Nasen Kehlkopfheilkd"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2017.09.008","article-title":"Salivary duct carcinoma: An aggressive salivary gland Malignancy with opportunities for targeted therapy","volume":"74","author":"Schmitt","year":"2017","journal-title":"Oral Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-019-05454-0","article-title":"Parotid salivary duct carcinoma: a single institution\u2019s 20-year experience","volume":"276","author":"Stodulski","year":"2019","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","article-title":"NCCN guidelines\u00ae Insights: head and neck cancers, version 2.2025","volume":"23","author":"Colevas","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103722","article-title":"Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review","volume":"9","author":"Prost","year":"2024","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105703","article-title":"Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma","volume":"125","author":"Uijen","year":"2022","journal-title":"Oral Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34892","article-title":"A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas","volume":"129","author":"Lee","year":"2023","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf106","article-title":"Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer","volume":"55","author":"Kano","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/162534","article-title":"Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001733","article-title":"Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma","volume":"36","author":"\u00c7olak","year":"2025","journal-title":"Anticancer Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-017-1196-8","article-title":"Impact of postoperative radiotherapy and HER2\/new overexpression in salivary duct carcinoma: A monocentric clinicopathologic analysis","volume":"193","author":"Haderlein","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.02.015","article-title":"Trastuzumab-based therapy is effective for salivary duct carcinoma: Case report and review of the literature","volume":"91","author":"Wu","year":"2019","journal-title":"Oral Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000513","article-title":"Nivolumab as a promising treatment option for metastatic salivary duct carcinoma","volume":"47","author":"Bugia","year":"2024","journal-title":"J Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jormas.2019.12.012","article-title":"Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature","volume":"121","author":"Poxleitner","year":"2020","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12885-024-13368-2","article-title":"Androgen receptor overexpression by immunohistochemistry in Malignant salivary gland tumors in Tanzania","volume":"25","author":"Matiku","year":"2025","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102993","article-title":"Palliative systemic therapy for locally advanced or metastatic salivary duct carcinoma: A comprehensive review","volume":"139","author":"Kanno","year":"2025","journal-title":"Cancer Treat Rev"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1590497\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:26Z","timestamp":1760933666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1590497\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1590497"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1590497","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1590497"}}